Study Treatment
Treatment consisted of daily oral thalidomide, fenofibrate, celecoxib, and alternating 21-day cycles of oral etoposide and cyclophosphamide, supplemented by intravenous bevacizumab and intraventricular therapy via an Ommaya reservoir consisting of alternating etoposide and liposomal or aqueous cytarabine. For an overview of the dosing schedule and dose modifications, see eTables 1 and 2 in 